BiofourmisConnect

Medicines made better

Our Approach

Access new avenues of care and bring evidence-based digital medicine to the patients who need it.

Using one of the only FDA-cleared algorithms, Biofourmis accelerates pharmaceutical product innovation and clinical research with a holistic, end-to-end solution to help improve patient outcomes.

Trusted by leading biopharma companies, payers, and patients.

DECENTRALIZED CLINICAL TRIALS

Transforming access to clinical development

Our proven remote patient management, integrated technology platform, and passion for data science provide you access to new clinical insights and reach a more inclusive patient population.

  • Development of digital biomarkers and expertise to enable the measurement of novel disease-specific endpoints
  • Innovative remote patient technologies and advanced analytics to process continuous and episodic data, enabling improved clinical R&D and unique patient insights
  • Regulatory expertise to help you navigate the complex drug development and commercialization landscape

Digital Biomarkers

Personalize treatment with intelligent data

Individual biometric data and machine learning algorithms enable objective clinical measures and generate new patient insights to drive personalized care.

  • 50+ in-house data scientists for development of proprietary algorithms to support new novel digital biomarkers

  • Gain longitudinal insights into disease progression for an individual patient, or for a collective population

  • Pre-validated wearable biosensors and connected devices, seamlessly integrated with our proprietary Biovitals platform

DIGITAL THERAPIES

Companion digital therapies to enhance drug development and commercialization

We partner with leading biopharmaceutical companies in the development of clinically-validated software-based therapeutics and digital patient engagement programs.

  • Patient-centric solutions with disease-specific journeys, notifications, vitals, and validated questionnaires and outcomes
  • Streamlined data collection enabled by wearable biosensors and connected devices, to drive medication titration and engage patients with real-time insights throughout their journey
  • Optimize medication adherence and generate evidence of value-based outcomes with digital patient engagement solutions

Partner Case Studies

Digital Medicine with Chugai Pharmaceutical CO., LTD

Chugai is objectively assessing pain associated with endometriosis to better understand its pathology and treatment.

Decentralized Clinical Trials with the University of Hong Kong

The University of Hong Kong is using the Biovitals Index to remotely monitor and identify COVID-19-related physiological biomarkers that indicate deterioration in patients.

Commercialization with Novartis

Novartis is partnering with Biofourmis to monitor heart failure patients who are taking Novartis’ drug to reduce hospital readmissions and emergency room visits.

What our partners are saying

“Through the partnership with Biofourmis, a leading company in research, development, and commercialization of digital medicine, Chugai will set out to objectively assess pain associated with endometriosis and better understand its pathology.”

Satoko Shisai, Chugai’s Vice President, Head of Digital & IT Supervisory Division

Biofourmis Digital Medicine Pipeline

Our digital medicine portfolio covers a range of patient conditions, including heart failure, acute coronary syndrome, COPD, oncology, and chronic pain.

Access The Whitepaper

Accelerating Biopharmaceutical Innovation with Digital Therapeutics to Improve Patients' Quality of Life

Learn more about how you can accelerate innovation with digital therapeutics to improve patient outcomes.

Deliver better patient outcomes with Biofourmis digital medicine